Skip to main content
Top
Published in: Tumor Biology 4/2013

01-08-2013 | Research Article

RETRACTED ARTICLE: CYP2D6 T188C variant is associated with lung cancer risk in the Chinese population

Authors: Yan Huang, Xin Liu, Xin Kuang, Duanfang Liao

Published in: Tumor Biology | Issue 4/2013

Login to get access

Abstract

The CYP2D6 gene has been suggested to play an important role in the pathogenesis of lung cancer. However, the results have been inconsistent. In this study, we performed a meta-analysis to clarify the association of CYP2D6 T188C variant with lung cancer. Published literature from PubMed, Embase, Chinese National Knowledge Infrastructure and Wanfang data were retrieved. Pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated using fixed- or random-effects model. A total of nine studies (1,516 lung cancer cases and 1,950 controls) for CYP2D6 T188C variant were included in the meta-analysis. The meta-analysis indicated that compared with CYP2D6 TT genotype, non-TT genotype (CC or CT) was significantly associated with lung cancer in the Chinese (OR = 1.61, 95 % CI = 1.38–1.87, p < 0.001), with no evidence of between-study heterogeneity (I 2 = 0.0 %, p = 0.991). The sensitivity analysis indicated that the association was stable and no publication bias was detected. The present meta-analysis supported the positive association of CYP2D6 T188C variant with lung cancer in the Chinese. Further large-scale studies with the consideration for gene–gene/gene–environment interactions should be conducted to investigate the association.
Literature
1.
2.
go back to reference Piskac-Collier AL, Monroy C, Lopez MS, Cortes A, Etzel CJ, Greisinger AJ, et al. Variants in folate pathway genes as modulators of genetic instability and lung cancer risk. Genes Chromosomes Cancer. 2011;50:1–12.CrossRefPubMed Piskac-Collier AL, Monroy C, Lopez MS, Cortes A, Etzel CJ, Greisinger AJ, et al. Variants in folate pathway genes as modulators of genetic instability and lung cancer risk. Genes Chromosomes Cancer. 2011;50:1–12.CrossRefPubMed
3.
go back to reference Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther. 1993;57:129–60.CrossRefPubMed Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther. 1993;57:129–60.CrossRefPubMed
4.
go back to reference Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229–43.CrossRefPubMed Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229–43.CrossRefPubMed
5.
go back to reference Gao Y, Zhang Q. Polymorphisms of the GSTM1 and CYP2D6 genes associated with susceptibility to lung cancer in Chinese. Mutat Res. 1999;444:441–9.CrossRefPubMed Gao Y, Zhang Q. Polymorphisms of the GSTM1 and CYP2D6 genes associated with susceptibility to lung cancer in Chinese. Mutat Res. 1999;444:441–9.CrossRefPubMed
6.
go back to reference Gu Y, Zhang S, Lai B, Wang H, Zhan X. Relationship between genetic polymorphism of metabolizing enzymes and lung cancer susceptibility. Chin J Lung Cancer. 2004;7:112–7. Chinese. Gu Y, Zhang S, Lai B, Wang H, Zhan X. Relationship between genetic polymorphism of metabolizing enzymes and lung cancer susceptibility. Chin J Lung Cancer. 2004;7:112–7. Chinese.
7.
go back to reference Li WY, Lai BT, Zhan XP. The relationship between genetic polymorphism of metabolizing enzymes and the genetic susceptibility to lung cancer. Chin J Epidemiol. 2004;25:1042–5. Chinese. Li WY, Lai BT, Zhan XP. The relationship between genetic polymorphism of metabolizing enzymes and the genetic susceptibility to lung cancer. Chin J Epidemiol. 2004;25:1042–5. Chinese.
8.
go back to reference Guo Z, Zhou Q, Zhu W, Li D, Yuan T, Wang Y, et al. A case–control study on the association between genetic polymorphisms of metabolizing enzymes CYP2D6 and susceptibility to lung cancer. Chin J Lung Cancer. 2005;8:89–94. Chinese. Guo Z, Zhou Q, Zhu W, Li D, Yuan T, Wang Y, et al. A case–control study on the association between genetic polymorphisms of metabolizing enzymes CYP2D6 and susceptibility to lung cancer. Chin J Lung Cancer. 2005;8:89–94. Chinese.
9.
go back to reference Liang GY. Studies on susceptibility genes of lung cancer in Chinese Han population and rapid detection techniques of single nucleotide polymorphisms. Doctoral Dissertation of Southeast University, 2005; 1–108. Chinese. Liang GY. Studies on susceptibility genes of lung cancer in Chinese Han population and rapid detection techniques of single nucleotide polymorphisms. Doctoral Dissertation of Southeast University, 2005; 1–108. Chinese.
10.
go back to reference Gu YF, Zhang ZD, Zhang SC, Zheng SH, Jia HY, Gu SX. Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility. Chin Med J. 2007;87:3064–8. Chinese. Gu YF, Zhang ZD, Zhang SC, Zheng SH, Jia HY, Gu SX. Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility. Chin Med J. 2007;87:3064–8. Chinese.
11.
go back to reference Yan Z, Wu YM, Wu YJ. CYP2D6*10 polymorphisms and lung cancer susceptibility. Acta Acad Med Sin. 2008;30:564–8. Chinese. Yan Z, Wu YM, Wu YJ. CYP2D6*10 polymorphisms and lung cancer susceptibility. Acta Acad Med Sin. 2008;30:564–8. Chinese.
12.
go back to reference Zhang JJ. Single nucleotide polymorphisms of CYP2D6 gene G4268C, C188T and ERCC1 gene C8092A and their genetic susceptibility to lung cancer. Master's thesis of China Medical University, 2010; 1–37. Zhang JJ. Single nucleotide polymorphisms of CYP2D6 gene G4268C, C188T and ERCC1 gene C8092A and their genetic susceptibility to lung cancer. Master's thesis of China Medical University, 2010; 1–37.
13.
go back to reference Zhou JL, Yao ZJ, Zeng ZP, Zhao XR, Xu Y, Cai XL, et al. Case–control study for the relationship of CYP1A1 and CYP2D6 polymorphisms with the genetic susceptibility to lung cancer. Acad J Guangdong Coll Pharm. 2011;27:528–31. Chinese. Zhou JL, Yao ZJ, Zeng ZP, Zhao XR, Xu Y, Cai XL, et al. Case–control study for the relationship of CYP1A1 and CYP2D6 polymorphisms with the genetic susceptibility to lung cancer. Acad J Guangdong Coll Pharm. 2011;27:528–31. Chinese.
14.
15.
go back to reference Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
16.
go back to reference Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMed Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMed
18.
go back to reference Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol. 1997;51:389–93.CrossRefPubMed Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol. 1997;51:389–93.CrossRefPubMed
19.
go back to reference Zhou LP, Luan H, Dong XH, Jin GJ, Man DL, Shang H. Genetic variants of CYP2D6 gene and cancer risk: a HuGE systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;13:3165–72.CrossRefPubMed Zhou LP, Luan H, Dong XH, Jin GJ, Man DL, Shang H. Genetic variants of CYP2D6 gene and cancer risk: a HuGE systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;13:3165–72.CrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: CYP2D6 T188C variant is associated with lung cancer risk in the Chinese population
Authors
Yan Huang
Xin Liu
Xin Kuang
Duanfang Liao
Publication date
01-08-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0755-6

Other articles of this Issue 4/2013

Tumor Biology 4/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine